Cardinal Health expands home care business with two tuck-in acquisitions

Big acquisition, but too little financial detail for investors to judge the payoff.

What the company is saying

Cardinal Health is positioning itself as a consolidator and innovator in the at-home healthcare delivery space, emphasizing its commitment to growth through strategic acquisitions. The company claims these two deals—acquiring AdaptHealth's Diabetes Health business and Strive Medical for a combined $360 million in cash—will accelerate its at-Home Solutions growth strategy and enhance its existing platform. Management highlights customer reach, citing more than 225,000 annual patients from AdaptHealth's business and over 20,000 from Strive Medical, and touts the onboarding of nearly 500,000 new customers since a prior acquisition. The announcement repeatedly frames these moves as transformative, using language like "accelerate growth," "enhance the framework," and "unique digital referral pathway," but provides no hard financials beyond transaction value and customer counts. The company asserts that the deals are expected to be accretive to non-GAAP earnings per share within 12 months of closing, but does not disclose any supporting numbers or pro forma impact. The tone is upbeat and confident, projecting a sense of inevitability about the benefits, while downplaying or omitting any discussion of integration risks, cost synergies, or the financial health of the acquired businesses. Notable individuals named include Jason Hollar (CEO) and Rob Schlissberg (President of at-Home Solutions), both of whom are institutionally significant as the architects of this strategy, but no external investors or third-party endorsements are mentioned. The messaging fits a classic M&A playbook: focus on scale, customer reach, and future earnings accretion, while providing minimal detail on the underlying economics or execution hurdles.

What the data suggests

The only concrete numbers disclosed are the $360 million cash outlay for both acquisitions, the annual customer counts for the acquired businesses (225,000+ for AdaptHealth's Diabetes Health and 20,000+ for Strive Medical), and the onboarding of nearly 500,000 new customers since the prior ADS deal. There is no revenue, EBITDA, margin, or cash flow data for either acquired entity, nor for Cardinal Health's at-Home Solutions segment, making it impossible to assess the financial trajectory or profitability impact. The claim that the deals will be accretive to non-GAAP EPS within 12 months is entirely forward-looking and unsupported by any actual figures or pro forma analysis. No information is provided on purchase price multiples, expected synergies, integration costs, or the financial health of the targets. The lack of period-over-period comparisons or historical performance data for the acquired businesses further limits any assessment of growth or value creation. An independent analyst, relying solely on these disclosures, would conclude that while the transaction size and customer reach are material, the absence of financial transparency makes it impossible to judge whether these are good deals or value-destructive. The data quality is poor for investment analysis, as key metrics are missing and the narrative is not substantiated by hard evidence.

Analysis

The announcement is positive in tone, highlighting Cardinal Health's entry into definitive agreements to acquire two businesses for $360 million in cash. However, the majority of key claims are forward-looking, including the expectation that the transactions will be accretive to non-GAAP EPS within 12 months of closing. There is no disclosure of revenue, EBITDA, or profitability metrics for the acquired businesses, nor for the at-Home Solutions segment, limiting the ability to assess the true financial impact. The capital outlay is significant, and the benefits are not immediate, as the deals are subject to regulatory approvals and closing conditions. The narrative inflates the signal by emphasizing strategic acceleration and platform-building without providing measurable financial evidence. The data supports only the transaction value and customer counts, not the claimed strategic or financial benefits.

Risk flags

• ●Lack of financial disclosure is a major risk: The announcement omits revenue, EBITDA, margin, and cash flow data for both acquired businesses, making it impossible for investors to assess whether the $360 million outlay is justified or value-accretive. This lack of transparency is a red flag for any M&A transaction.
• ●Majority of claims are forward-looking: Most of the key benefits—such as earnings accretion and strategic acceleration—are projections rather than realized outcomes. Investors face the risk that these expectations may not materialize, especially without supporting data.
• ●Execution and integration risk: The deals are not yet closed and are subject to regulatory approvals and other conditions. Even after closing, integrating two new businesses into Cardinal Health's at-Home Solutions platform could encounter operational challenges, cost overruns, or cultural mismatches.
• ●Capital intensity with uncertain payoff: The $360 million cash outlay is significant, and with no disclosed financials for the targets, there is a risk that the return on investment will fall short of expectations. High capital intensity amplifies the consequences of any misstep.
• ●No disclosure of synergies or cost savings: The company does not provide any estimates or targets for cost synergies, revenue enhancements, or integration expenses, leaving investors in the dark about how value will be created beyond customer counts.
• ●Absence of pro forma or comparative metrics: Without period-over-period data or pro forma financials, investors cannot benchmark the impact of these deals against Cardinal Health's existing operations or industry norms. This makes it difficult to gauge whether the acquisitions are transformative or merely incremental.
• ●Regulatory and closing risk: The announcement notes that the transactions are subject to customary closing conditions and regulatory approvals, which introduces uncertainty about timing and the possibility that one or both deals could be delayed or fall through.
• ●Reliance on management's narrative: With no third-party validation or external investor participation disclosed, the investment case rests entirely on management's assertions. This increases the risk that the narrative is overly optimistic or incomplete.

Bottom line

For investors, this announcement signals that Cardinal Health is making a substantial bet on expanding its at-home healthcare platform through two acquisitions totaling $360 million in cash. However, the lack of any disclosed revenue, EBITDA, or profitability metrics for the acquired businesses means there is no way to independently assess whether these deals are likely to create value or simply add scale without profit. The company's narrative is confident and growth-oriented, but almost all of the claimed benefits are forward-looking and unsupported by hard data. The involvement of senior management as deal architects is notable, but there are no external institutional investors or third-party endorsements to lend additional credibility. To change this assessment, Cardinal Health would need to disclose detailed financials for the acquired businesses, including revenue, margins, and expected synergies, as well as pro forma impact on the at-Home Solutions segment. Key metrics to watch in the next reporting period include actual revenue and earnings contributions from the new acquisitions, integration progress, and any updates on regulatory approvals or closing timelines. At this stage, the announcement is worth monitoring but not acting on, as the signal is weak and the risks are high due to insufficient disclosure. The single most important takeaway is that investors should demand much greater financial transparency before considering this M&A activity as a reason to buy or sell Cardinal Health shares.

Announcement summary

(NYSE: CAH) Cardinal Health announced it has entered into two definitive agreements to acquire the Diabetes Health business of AdaptHealth Corp. (NASDAQ: AHCO) and Strive Medical for a combined total of approximately $360 million in cash, subject to working capital adjustments. The Diabetes Health business of AdaptHealth serves more than 225,000 people annually, while Strive Medical serves more than 20,000 people annually. Since closing the original Advanced Diabetes Supply (ADS) transaction, Cardinal Health's at-Home Solutions business has onboarded nearly 500,000 new customers and launched the ContinuCare Pathway program. The transactions are subject to customary closing conditions, including receipt of required regulatory approvals. The company states these transactions are expected to be accretive to non-GAAP earnings per share in the first 12 months following close. J.P. Morgan Securities LLC served as financial advisor to Cardinal Health on both acquisitions, with Skadden, Arps, Slate, Meagher & Flom LLP and DLA Piper as legal advisors for the AdaptHealth acquisition, and BakerHostetler LLP and DLA Piper LLP for the Strive Medical acquisition.

Disagree with this article?